Posts

Posted on

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Announces Participation in Upcoming Investor Conferences

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:

  • Berenberg U.S. CEO Conference on Thursday, November 12, 2020 (one-on-one and group meetings only)
  • Stephens Annual Investment Conference on Thursday, November 19, 2020 at 8:00 a.m. PST
  • Piper Sandler 32nd Annual Healthcare Conference (a pre-recorded fireside chat presentation will be available for viewing beginning on Monday, November 23, 2020; management will participate in one-on-one and group meetings on Wednesday, December 2, 2020)

A live and archived webcast for these event, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent inject® W device in the United States in October 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Chris Lewis

Director, Investor Relations, Corporate Strategy & Development

(949) 481-0510

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Medical Devices Health Pharmaceutical Optical

MEDIA:

Posted on

Dillard’s, Inc. to Report Third Quarter Results

Dillard’s, Inc. to Report Third Quarter Results

LITTLE ROCK, Ark.–(BUSINESS WIRE)–
Dillard’s, Inc. (NYSE: DDS) will announce results for the 13 and 39 weeks ended October 31, 2020 tomorrow after the close of the New York Stock Exchange.

Julie J. Guymon

Director of Investor Relations

(501) 376-5965

[email protected]

KEYWORDS: Arkansas United States North America

INDUSTRY KEYWORDS: Retail Department Stores Fashion

MEDIA:

Logo
Logo
Posted on

Humana Inc. to Present at the Wolfe Research Healthcare Conference

Humana Inc. to Present at the Wolfe Research Healthcare Conference

LOUISVILLE, Ky.–(BUSINESS WIRE)–
Humana Inc. (NYSE: HUM) announced today that Brian A. Kane, Chief Financial Officer, will make a presentation to investors at the Wolfe Research Healthcare Conference on Thursday, November 19, 2020, at 7:50 a.m. Eastern time.

A live audio webcast of the presentation will be available via Humana’s Investor Relations page at humana.com. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run a system test and download any free software needed for access purposes.

About Humana

Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.

To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at humana.com, including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases
  • Calendar of events
  • Corporate Governance information

 

Amy Smith

Humana Investor Relations

(502) 580-2811

e-mail: [email protected]

Kelley Murphy

Humana Corporate Communications

(502) 224-1755

e-mail: [email protected]

KEYWORDS: Kentucky United States North America

INDUSTRY KEYWORDS: General Health Health Professional Services Insurance Managed Care

MEDIA:

Posted on

Evolving Systems Reports Third Quarter 2020 Financial Results

ENGLEWOOD, Colo., Nov. 11, 2020 (GLOBE NEWSWIRE) — Evolving Systems, Inc. (NASDAQ: EVOL) (the “Company”), a leader in real-time digital engagement, today reported financial results for its third quarter ended September 30, 2020.

20
20
Third
Quarter
Highlights:

  • Third quarter revenue of $6.8 million, an increase of $0.5 million from the previous quarter results
  • Year to date revenue of $19.4 million
  • The Company has generated positive cash flow from operations in 2020
  • Third quarter operating profit was $0.4 million, net income of $0.1 million
  • Adjusted earnings before interest, taxes, depreciation, and amortization (“adjusted EBITDA”) for the third quarter was $0.8 million

“As we continue to navigate through these historic times around the globe, we are proud to say we have been able to continue to generate positive operational performance, as our service revenue has increased from the corresponding period a year ago and we have generated positive cash flow for the year. Throughout our years of global service, we have developed a culture of successfully managing our business through telework. We continue to leverage our ability to implement and provide support remotely and have noted a relatively limited effect on our operations during this pandemic. We are working with existing and new clients, helping them to explore new ways of using our products and services to enhance their businesses during these unusual times. We have seen continued impact on our ability to interact with our clients in the traditional modes of sales and business development; although this has slowed our expected growth, we were excited to make the gains that we have,” said Matthew Stecker, Chief Executive Officer and Executive Chairman of the Company.

Third
Quarter
and Year
–
to
–
Date
20
20
Results

Total revenue for the third quarter ended September 30, 2020 was $6.8 million, a $0.7 million increase from the three months ended September 30, 2019. The change was primarily related to increased revenue from upgrades and new projects partially offset by project completion or reduction in orders from existing clients in the corresponding period in 2019. Total revenue for the nine months ended September 30, 2020 was $19.4 million, or approximately a 1.7% increase from $19.1 million in the same period a year ago, predominantly related to increased revenue from upgrades and new projects recognized this year, partially offset by one-time licensing fees recognized in the prior year period. Services revenue, which is mostly recurring in nature, was $19.0 million year-to-date, an increase year-over-year of $1.1 million, or 6.1% from $17.9 million during the comparable year-ago period. Services revenue, which includes revenues from the Company’s preference for managed services over perpetual licensing, comprised approximately 98% of total revenues for the nine months ended September 30, 2020.

The Company reported gross profit margins, excluding depreciation and amortization, of approximately 68.5% for the quarter ended September 30, 2020, as compared to gross profit margins of approximately 64.9% during the comparable year-ago period. This increase in gross margin was primarily related to the increased revenue recognized on new projects and upgrades. For the nine months ended September 30, 2020, the Company reported gross profit margins, excluding depreciation and amortization, of approximately 66.7%, as compared to gross profit margins of approximately 67.2% for the nine months ended September 30, 2019. This decrease in gross margin was primarily related to the product and service mix inclusive of the higher licensing revenue in the prior year period.

Total operating expenses were $4.3 million in each of the quarters ended September 30, 2020 and 2019. Expenses related to travel and marketing costs were lower due to the travel reductions during the global pandemic and were primarily offset by increases in general and administrative costs related to local accounting fees. Total operating expenses were $12.4 million for the nine months ended September 30, 2020. Total operating expenses were $20.8 million for the nine months ended September 30, 2019; or $14.1 million after excluding the $6.7 million goodwill impairment charge in 2019. The decrease of approximately $1.7 million was related to the mix of hours as delivery staff focused on customers’ projects, not product development as in the prior year, and a decrease in overall resourcing costs. There were also reductions in the Company’s accounting fees, incentive compensation expense, and the aforementioned decreases in travel and marketing costs, mainly due to the travel restrictions.

The Company reported operating profit of $0.4 million and net income of $0.1 million for the three months ended September 30, 2020, as compared to operating loss of $0.3 million and a net loss of $0.2 million for the three months ended September 30, 2019. The Company reported adjusted EBITDA of $0.8 million for the quarter ended September 30, 2020 compared to $0.1 million for the same period a year ago. Adjusted EBITDA for the nine months ended September 30, 2020 was $1.5 million compared to an adjusted EBITDA loss of $0.2 million for the first nine months in 2019.

Cash and cash equivalents as of September 30, 2020 were $3.5 million, an increase of 13.3% compared to $3.1 million as of December 31, 2019. At September 30, 2020, contract receivables, net of allowance for doubtful accounts, were $3.4 million, a decrease of $3.3 million compared to $6.7 million as of December 31, 2019. Unbilled work-in-progress was $3.4 million at September 30, 2020, an increase of $2.3 million compared to December 31, 2019. Working capital as of September 30, 2020 increased to $4.8 million as compared to $3.8 million as of December 31, 2019. This is primarily related to paydown of our loan with East West Bank, which is scheduled to be retired at the end of the year. The change also includes an alternative minimum tax refund expected in the current year which was previously recorded in our deferred tax assets. The Company believes it has sufficient cash on hand and working capital liquidity to fund its business and continued strategic investments for at least the next twelve months.

Matthew Stecker concluded: “As the year draws to a close, we continue to take the necessary actions to service our clients to our fullest ability through the on-going global pandemic. We must focus on continual business transformation, increasing innovation, and product enhancements while identifying opportunities to meet our customers’ changing needs. Our strong customer footprint and decades of proven performance gives us a significant head-start to maintain our business trend during these uncertain times. We selectively seek new opportunities whether through potential accretive acquisitions, joint ventures, or strategic partnerships to drive both top- and bottom-line performance to bring our shareholders long-term value.”

Conference Call

The Company will be conducting a conference call and webcast on Wednesday, November 11, 2020 at 5:00 p.m. Eastern Time and 3:00 p.m. Mountain Time. To access a live video webcast of the call, please click the ‘Investors’ tab on the Company’s website at https://www.evolving.com/investors and then click the ‘Q3 earnings call’ icon on the left. A replay of the webcast will be accessible at that website through February 11, 2021.

Non-GAAP Financial Measures

The Company reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of non-GAAP net income and diluted net income per share and adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, impairment, stock compensation, restructuring and gain/loss on foreign exchange transactions). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Investors and financial analysts who follow the Company use non-GAAP net income and non-GAAP diluted income per share to compare the Company against other companies. Adjusted EBITDA can be useful for lenders as an indicator of earnings available to service debt. Non-GAAP financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with GAAP.

About Evolving Systems®

Evolving Systems, Inc. (NASDAQ: EVOL) is a provider of real-time digital engagement solutions and services to more than 100 customers in over 60 countries worldwide. The Company’s portfolio includes market-leading solutions and services for real-time analytics, customer acquisition, customer value management and loyalty for telecom, retail and financial services companies. Founded in 1985, the Company has its headquarters in Englewood, Colorado, with offices in Asia, Europe, Africa, and North America. For more information, please visit www.evolving.com or follow us on Twitter at http://twitter.com/EvolvingSystems.

CAUTIONARY STATEMENT

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, based on current expectations, estimates and projections that are subject to risk. Specifically, statements about the market for, and performance of, the Company’s products, its ability to successfully integrate its solutions with existing customer network systems, the Company’s ability to timely make all future payments under its debt facility, the Company’s business strategy and the Company’s cash runway are forward-looking statements. These statements are based on the Company’s expectations and are naturally subject to uncertainty and changes in circumstances. Readers should not place undue reliance on these forward-looking statements. Actual results could vary materially from these expectations. For a more extensive discussion of Evolving Systems’ business, and important risk factors that could cause actual results to differ materially from those contained in the forward-looking statements, please refer to the Company’s filings and reports filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations Contact:

Alice Ahern
Investor Relations
Evolving Systems
Tel: 1-844-732-5898
Email: [email protected]

 
 
EVOLVING SYSTEMS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS
(in thousands, except per share data)
(unaudited)
   
  September 30,   December 31,
  2020   2019
ASSETS          
Current assets:          
Cash and cash equivalents $ 3,486     $ 3,076  
Contract receivables, net of allowance for doubtful accounts   3,409       6,732  
Unbilled work-in-progress   3,356       1,105  
Prepaid and other current assets   1,849       1,594  
Income taxes receivable   819       953  
Total current assets   12,919       13,460  
Property and equipment, net   531       482  
Amortizable intangible assets, net   2,918       3,665  
Operating leases – right-of-use assets   979       1,205  
Deferred income taxes, net   631       1,000  
Total assets $ 17,978     $ 19,812  
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Term loan – current $ 428     $ 1,577  
Accounts payable and accrued liabilities   4,042       3,827  
Lease obligations — operating leases   291       321  
Unearned revenue   3,321       3,971  
Total current liabilities   8,082       9,696  
Long-term liabilities:          
Term loan, net   319       122  
Lease obligations, net   680       876  
Total liabilities   9,081       10,694  
           
Stockholders’ equity:          
Common stock   12       12  
Additional paid-in capital   99,714       99,555  
Treasury stock   (1,253 )     (1,253 )
Accumulated other comprehensive loss   (10,489 )     (10,053 )
Accumulated deficit   (79,087 )     (79,143 )
Total stockholders’ equity   8,897       9,118  
Total liabilities and stockholders’ equity $ 17,978     $ 19,812  
               

EVOLVING SYSTEMS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
                       
  Three Months Ended   Nine Months Ended
  September 30,   September 30,
    2020       2019       2020       2019  
REVENUE                      
License fees $ 83     $ 185     $ 387     $ 1,152  
Services   6,691       5,928       19,001       17,914  
Total revenue   6,774       6,113       19,388       19,066  
                       
COSTS OF REVENUE AND OPERATING EXPENSES                      
Costs of revenue, excluding depreciation and amortization   2,132       2,144       6,456       6,249  
Sales and marketing   1,511       1,815       4,516       5,574  
General and administrative   1,352       979       3,875       3,985  
Product development   1,094       1,183       3,168       3,676  
Depreciation   58       61       158       150  
Amortization   236       232       704       704  
Goodwill impairment loss   —       —       —       6,687  
Total costs of revenue and operating expenses   6,383       6,414       18,877       27,025  
                       
Income (loss) from operations   391       (301 )     511       (7,959 )
                       
Other income (expense)                      
Interest income   1       1       4       10  
Interest expense   0       (71 )     (65 )     (255 )
Other (loss) income, net   (1 )     13       18       1  
Foreign currency exchange gain (loss) income   (107 )     250       240       183  
Other (expense) income, net   (107 )     193       197       (61 )
                       
Income (loss) from operations before income taxes   284       (108 )     708       (8,020 )
Income tax expense   148       109       652       296  
Net income (loss) $ 136     $ (217 )   $ 56     $ (8,316 )
                       
Basic earnings (loss) per common share – net income (loss) $ 0.01     $ (0.02 )   $ 0.00     $ (0.68 )
                       
Diluted earnings (loss) per common share – net income (loss) $ 0.01     $ (0.02 )   $ 0.00     $ (0.68 )
                       
Weighted average basic shares outstanding   12,195       12,163       12,185       12,154  
Weighted average diluted shares outstanding   12,258       12,163       12,275       12,154  
                       
                       
                       
EVOLVING SYSTEMS, INC.
Reconciliation of GAAP to Non-GAAP Measures
(in thousands, except per share data)
(unaudited)
                       
  Three Months Ended   Nine Months Ended
  September 30,   September 30,
    2020       2019       2020       2019  
Adjusted EBITDA:                      
Net income (loss) $ 136     $ (217 )   $ 56     $ (8,316 )
Depreciation   58       61       158       150  
Amortization of intangible assets   236       232       704       704  
Stock-based compensation expense   92       70       159       263  
Goodwill impairment loss   —       —       —       6,687  
Interest expense and other (benefit), net   107       (193 )     (197 )     61  
Income tax expense   148       109       652       296  
Adjusted EBITDA $ 777     $ 62     $ 1,532     $ (155 )
                       
                       
Non-GAAP net (loss) income:                      
GAAP net income (loss) $ 136     $ (217 )   $ 56     $ (8,316 )
Amortization of intangible assets   236       232       704       704  
Stock-based compensation expense   92       70       159       263  
Goodwill impairment loss   —       —       —       6,687  
Income tax adjustment for non-GAAP*   (57 )     (53 )     (147 )     (169 )
Non-GAAP net income (loss) $ 407     $ 32     $ 772     $ (831 )
                       
Diluted net income (loss) per share                      
GAAP $ 0.01     $ (0.02 )   $ 0.00     $ (0.68 )
Non-GAAP $ 0.03     $ 0.00     $ 0.06     $ (0.07 )
Shares used to compute diluted net income (loss) per share   12,258       12,163       12,275       12,154  
                       
                       
* The estimated income tax for non-GAAP net income is adjusted by the amount of additional expense that we would accrue if we used non-GAAP results instead of GAAP results in the calculation of our tax liability, taking into account which tax jurisdiction each of the above adjustments would be made and the tax rate in that jurisdiction.

Posted on

Bristol Myers Squibb to Participate in Wolfe Research’s 2nd Annual Virtual Healthcare Conference

Bristol Myers Squibb to Participate in Wolfe Research’s 2nd Annual Virtual Healthcare Conference

NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Wolfe Research’s 2nd Annual Virtual Healthcare Conference, which will be webcast on Wednesday, November 18, 2020. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will answer questions about the company at 9:15 a.m. EST.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Bristol Myers Squibb

Media:

[email protected]

Investor Relations:

Tim Power

609-252-7509

[email protected]

Nina Goworek

908-673-9711

[email protected]

KEYWORDS: New York New Jersey United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Public Relations/Investor Relations General Health Health Infectious Diseases Communications Other Health

MEDIA:

Logo
Logo
Posted on

Enable Midstream to Participate in Upcoming Conferences

Enable Midstream to Participate in Upcoming Conferences

OKLAHOMA CITY–(BUSINESS WIRE)–
Enable Midstream Partners, LP (NYSE: ENBL) announced today that members of its senior management are scheduled to meet with investors at the following upcoming virtual investor conferences:

  • RBC Capital Markets Midstream and Energy Infrastructure Conference on Wednesday, Nov. 18, 2020
  • MUFG Oil & Gas Conference on Wednesday, Dec. 2, 2020
  • Wells Fargo Midstream and Utility Symposium on Wednesday, Dec. 9, 2020

The presentation materials used at these conferences will be available for download on the investor page of Enable’s website at https://investors.enablemidstream.com.

ABOUT ENABLE MIDSTREAM PARTNERS

Enable owns, operates and develops strategically located natural gas and crude oil infrastructure assets. Enable’s assets include approximately 14,000 miles of natural gas, crude oil, condensate and produced water gathering pipelines, approximately 2.6 Bcf/d of natural gas processing capacity, approximately 7,800 miles of interstate pipelines (including Southeast Supply Header, LLC of which Enable owns 50 percent), approximately 2,200 miles of intrastate pipelines and seven natural gas storage facilities comprising 84.5 billion cubic feet of storage capacity. For more information, visit https://enablemidstream.com.

Media

Leigh Ann Williams

(405) 553-6947

Investor

Matt Beasley

(405) 558-4600

KEYWORDS: Oklahoma United States North America

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo
Posted on

Mettler-Toledo International Inc. Announces Webcast of Presentation at the Stifel 2020 Virtual Healthcare Conference

Columbus, OH, Nov. 11, 2020 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 9:20 a.m Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.mt.com/investors.  A replay of the webcast will be available for seven days.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.    
    

Mary T. Finnegan
Investor Relations
+1-614-438-4748

Posted on

ES&S Equipment Efficiently, Accurately, Securely Records Election History

Key official describes 2020 presidential election as one of the smoothest in memory

Omaha, Nebraska, Nov. 11, 2020 (GLOBE NEWSWIRE) — As elections officials across the United States work toward final certification of results for the 2020 general election, they are consistently praising the performance of the people, processes and equipment that made the election administration a success.

“From an administrative perspective, the 2020 general election couldn’t have gone better,” said Wendy Satory Link, Supervisor of Elections in Palm Beach County, Florida, which uses equipment from Election Systems & Software (ES&S). “We are 100 percent confident in the accuracy of results and are very pleased with the support from our staff and election equipment partners. Everyone worked hard, day and night, to make sure we were ready, and that preparation paid off in terms of an accurate and efficient reporting process.”

All across the nation, jurisdictions adjusted and enhanced their elections administration to handle the record number of ballots cast. Nearly 150 million Americans voted in the 2020 presidential election, making the 2020 turnout rate the highest since 1900. In Wyoming, which uses ES&S voting equipment statewide, a record voter turnout almost doubled numbers between the primary and general elections this year, with unofficial returns in the general election amounting to a record 278,503 votes cast statewide. 

“I am incredibly thankful for the successful elections that took place last week across Wyoming,” said Wyoming Secretary of State Edward Buchanan. “This achievement was possible due to our hardworking county clerks, poll workers and new election equipment from ES&S standardizing our election process throughout Wyoming.”

Nebraska also uses ES&S voting systems statewide. With a greater than 75 percent turnout and more than 950,000 votes cast, clerks across the state also doubled the number of ballots counted since the spring election,  which had previously shattered election records in the state.

“ES&S provided us with a high level of support which was instrumental in helping us to get through a challenging general election,” said Nebraska Secretary of State Bob Evnen.

“The level of preparation for administering this election was unprecedented,” said Tom Burt, ES&S President and CEO. “Elections officials, staff and volunteers across America worked day and night to get ready, and every jurisdiction ES&S serves experienced an accurate, reliable and efficient recording of votes. That’s a testament to the people, processes and equipment.”

ES&S equipment is used in multiple jurisdictions in Pennsylvania, including in Philadelphia, where more than 700,000 ballots were cast. Considering the two-fold challenge of the Covid-19 pandemic and the record volume of absentee or mail-in ballots, the City set up a massive vote-counting center with 12 ES&S high speed central tabulation machines as the centerpiece of the operation. The day after the Nov. 3 election, Pennsylvania’s Secretary of State Kathy Bookvar said, “It’s one of the smoothest, least-issues presidential elections that I’ve seen in any time I can possibly remember.”

In Milwaukee, which also used ES&S high speed central tabulation to process just under 170,000 ballots, the city had an equally impressive operation. Milwaukee Election Commission Executive Director Claire Woodall-Vogg told the Journal Sentinel she was proud of the election workers who “allowed Wisconsin to have election results in such a timely manner.” She went on to call their operation “smooth, accurate and transparent.”

To handle the increased number of ballots nationwide, ES&S worked with federal, state and local officials to ramp up capabilities and counting capacities. In fact, three times the amount of ES&S central count scanners were fielded for the 2020 November election than were in place for the 2016 presidential election. Specifically, in jurisdictions across America, ES&S had in place: 

Additionally, voters used more than 95,000 ES&S ExpressVote® and 7,300 ExpressVote® XL universal voting machines were in precincts across the country. With the unprecedented amount of equipment deployed to handle the increased volume of ballots cast, ES&S machines were lauded not only for their efficiency but for their accuracy and ease of use. 

“Each of our voting machines go through a tremendous amount of testing to prove accuracy and reliability,” said Steve Pearson, ES&S Senior Vice President of Certification. “To earn certification from the U.S. Elections Assistance Commission, every unit must consecutively read 1.5 million ballot positions correctly. High-speed scanners such as the DS850 can tabulate up to 300 ballots per minute. We work with federal, state and local election officials to ensure we not only meet but exceed every testing standard.”

In addition to tabulation successes, several jurisdictions also used new ExpressPoll® pollbook technology to quickly and steadily check in voters at the polls, including in jurisdictions in Alabama, Texas and South Carolina. In fact, ES&S worked with election officials in South Carolina to put more than 5,000 new ExpressPoll pollbooks in place in the final weeks leading up to Election Day, providing for a smooth election check-in process for voters.

“Our team of dedicated professionals worked with diligence, patience and perseverance to think through what our customers and their voters might need to have a successful election and they delivered on all accounts,” said Patrice Webb, ES&S Senior Vice President of Public Affairs. 

“This Election Day has been historic for our nation on so many levels,” said Kathy Rogers, ES&S Senior Vice President of Government Affairs. “We are deeply honored to play a role in helping Americans exercise their rights as they participate in our nation’s democracy, and we couldn’t be more pleased with the smooth and accurate execution of the voting process.”

ABOUT ES&S:
Election Systems & Software (ES&S) is the nation’s leading voting systems manufacturer. For more than 40 years, ES&S has been supporting elections by creating and providing secure, accurate and accessible voting equipment to jurisdictions across the country. Learn more about ES&S at www.essvote.com and on Facebook at facebook.com/essvote.

###

Attachment 

Katina Granger
Election Systems & Software (ES&S)
402-938-1300
[email protected]

Posted on

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

– Disease control observed in 92% of patients

– Conference call to be held today at 2:30pm PT

PR Newswire

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma. This data will be presented to attendees of the Annual Connective Tissue Oncology Society (“CTOS”) Conference on November 20, 2020 (Paper #16). Chondrosarcoma is an orphan disease and bone cancer with approximately 2,800 new patients diagnosed annually in the United States and the European Union. There are currently no therapeutics approved for the treatment of chondrosarcoma.

Inhibrx’s most advanced program, INBRX-109, is a precision-engineered, tetravalent DR5 agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.

  • Of the 12 patients evaluable for efficacy within the ongoing chondrosarcoma expansion cohort to date, disease control was observed in 11 of 12 patients (92%) and 8 of 12 patients (67%) had a decrease in their tumor burden by RECIST.
  • Two of the patients achieved partial responses with reductions in tumor size of 60% and 32% as of October 2020.
  • Based on these preliminary results, the observed disease control rate at the four-month follow-up was 8 of 12 subjects (67%) with 7 of 12 patients continuing on study. The longest disease control duration observed to date for a patient in this cohort was 33 weeks, or approximately eight months.
  • The safety and tolerability profile continued to be favorable with most patients, approximately 90%, experiencing no signs of hepatotoxicity. There have been no new serious or severe adverse events since Inhibrx’s last safety update in July 2020.
  • The trial is ongoing and an additional 10 patient slots were added, per investigator requests, to the chondrosarcoma cohort.

“I am quite pleased to see prolonged progression free survival in a disease that has been unresponsive to conventional therapies,” notes Dr. Sant P. Chawla, one of the principal investigators conducting the Phase 1 trial at the Sarcoma Oncology Center in Santa Monica, California.

“We believe the results in chondrosarcoma, a disease with a significant unmet need, are very promising. We are meeting with the Food and Drug Administration in the near future to discuss the design of a registration-enabling study that we anticipate initiating in the second quarter of next year,” said Mark Lappe, CEO for Inhibrx. “Additionally, this month, we will initiate dosing in patients with synovial sarcoma, as well as our first chemotherapy combination cohorts with INBRX-109 in pancreatic adenocarcinoma and epithelioid subtype malignant pleural mesothelioma.”

Conference Call Details
Inhibrx will hold a conference call to discuss these results today at 2:30 p.m. PT. Investors may join via the web: https://www.webcaster4.com/Webcast/Page/2560/38423 or may listen to the call by dialing (1-877-870-4263) from locations in the United States or (1-412-317-0790) from outside the United States. Please refer to Inhibrx, Inc. when calling in. Following the webcast, the presentation may be accessed through a link on the investors section of Inhibrx’s website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event. Inhibrx has also updated its corporate presentation which is available on the “Investors” section of its website at www.inhibrx.com.

About INBRX-109
INBRX-109 is a precisely engineered tetravalent single domain antibody (sdAb) based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death. A three-part, Phase 1 clinical trial was initiated in November 2018. Part 1, dose escalation, was completed in August 2019 with enrollment of 20 patients. INBRX-109 was well-tolerated, with no significant toxicities observed at doses up to and including the maximum administered dose of 30 mg/kg. No maximum tolerated dose was reached. Part 2, single agent dose expansion, commenced in September 2019, while Part 3, chemotherapy combination cohorts, initiated this month in epithelioid subtype malignant pleural mesothelioma and pancreatic adenocarcinoma.

About the Inhibrx sdAb Platform
Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary sdAb platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows for the combination of multiple binding units in a single molecule, enabling therapeutic candidates with precisely defined valency or multiple specificities that can achieve enhanced cell signaling or conditional target activation. An additional benefit of this platform is that these optimized, multi-functional entities can be manufactured using established processes that are commonly used to produce therapeutic proteins.

About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

Forward-Looking Statements
Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx’s and its investigators judgments and beliefs regarding the observed safety and efficacy to date of its therapeutic candidate, INBRX-109, discussions with and beliefs regarding future action by the U.S. Food and Drug Administration, and statements and beliefs regarding the future clinical development of INBRX-109. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx’s business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including under the heading “Risk Factors” in Inhibrx’s prospectus dated August 18, 2020 filed with the SEC on August 19, 2020 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:

Amy Conrad

Juniper Point
[email protected]
858-366-3243

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibrx-announces-positive-interim-results-from-the-phase-1-trial-of-inbrx-109-in-chondrosarcoma-patients-301171332.html

SOURCE Inhibrx, Inc.

Posted on

HubSpot to Present at the RBC Technology Conference

PR Newswire

CAMBRIDGE, Mass., Nov. 11, 2020 /PRNewswire/ — HubSpot (NYSE: HUBS), a leading customer relationship management (CRM) platform, today announced that Brian Halligan, the Company’s Chief Executive Officer, and Kate Bueker, the Company’s Chief Financial Officer, are scheduled to present virtually at the RBC Technology Conference on Tuesday, November 17, 2020 at 1:20 p.m. ET. All interested parties can access the webcast live on the Company’s investor relations website at ir.hubspot.com. The Company will also host virtual 1-on-1 investor meetings on the same day.

About HubSpot

HubSpot (NYSE: HUBS) is a leading customer relationship management (CRM) platform that provides software and support to help businesses grow better. The platform includes marketing, sales, service, and website management products that start free and scale to meet our customers’ needs at any stage of growth. Today, more than 95,000 customers across more than 120 countries use HubSpot’s powerful and easy-to-use tools and integrations to attract, engage, and delight customers.

Named Glassdoor’s #1 Best Place to Work in 2020, HubSpot has been recognized for its award-winning culture by Great Place to Work, Comparably, Fortune, Entrepreneur, Inc., and more. The company is headquartered in Cambridge, MA with offices in Dublin, Ireland; Singapore; Sydney, Australia; Tokyo, Japan; Berlin, Germany; Bogotá, Colombia; Paris, France; Ghent, Belgium; San Francisco, CA; and Portsmouth, NH.

Learn more at www.hubspot.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hubspot-to-present-at-the-rbc-technology-conference-301171225.html

SOURCE HubSpot